MoxDuo® CR (Q8011 CR)

The target market for the Company’s oral controlled release capsule, MoxDuo® CR, is doctors who are seeking products that will reduce the number of opioid doses necessary per day, extend the duration of effect to achieve true 12 hour pain control, and minimise side effects. QRxPharma believes its patented MoxDuo CR formulation will deliver all of these benefits.

Apart from lower amounts of active ingredients than competing products, MoxDuo CR has also been designed with patented features.

QRx Pharma

MoxDuo® CR (Q8011 CR)